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In clinical practice, the high incidence of metabolic abnormalities, such as diabetes 
and hyperlipidemia, seen in schizophrenic patients are the result of a complex inter-
action of a number of factors, including lifestyle, overactivity of the hypothalamic-
pituitary-adrenal axis, and antipsychotic medication. Antipsychotic-induced metabolic 
abnormalities have been thought to be due to insulin resistance caused by obesity, 
which is a major side-effect of antipsychotics. However, there is increasing evidence 
that second-generation antipsychotics can also have direct metabolic effects.
We investigated two similar groups of 9 non-obese, non-diabetic Japanese schizo-
phrenic patients taking either risperidone or olanzapine as monotherapy for 3–66 
weeks with no changes in their treatment for at least 3 weeks. The published Japanese 
deﬁ  nitions for obesity (BMI >25, waist measurement at umbilicus level >85 cm for 
males, >90 cm for females) and diabetes (fasting glucose > 110 mg/dL) were used 
(Matsuzawa et al 2005).
Metabolic markers (glucose, insulin, triglycerides, total cholesterol, and high-
density lipoprotein cholesterol) were measured in blood samples taken after 12 h fast-
ing. Subjects then ingested a 110 g glucose tolerance test cookie (Harano et al 2006) 
and blood was taken 2 h later for measurement of glucose, insulin, triglycerides, and 
remnant-like lipoprotein particles (RLP) cholesterol levels. Insulin resistance was as-
sessed by the homeostasis model assessment of insulin resistance (HOMA-IR) (Emoto 
et al 1999). RLP were measured as the unbound serum fraction in an immuno-afﬁ  nity 
mixed gel using monoclonal antibodies to apoA-I and apoB100 (Nakajima et al 1996). 
RLP-cholesterol levels were determined as the cholesterol fraction. 
Fasting values and those obtained 2 h after the glucose tolerance test are shown 
in Table 1. Plasma glucose levels remained within normal limits for both groups 
although those in the olanzapine group were signiﬁ  cantly increased after the test 
compared with fasting levels. Insulin levels were signiﬁ  cantly increased to a similar 
extent in both groups after the glucose tolerance test. No insulin resistance was seen 
in any patient.
The triglyceride levels were signiﬁ  cantly increased compared to fasting levels in 
the olanzapine group but not in the risperidone group. The value over the normal limit 
(>150 mg/dL) indicates that lipid metabolic abnormalities may occur in the olanzap-
ine group. In addition, the level of RLP-cholesterol in the olanzapine group was also 
signiﬁ  cantly increased compared to the risperidone group.
Higher fasting serum insulin levels have been found in schizophrenic patients treated 
with clozapine compared with those treated with conventional antipsychotics, suggesting 
possible insulin resistance (Melkersson et al 1999). Similarly treatment with olanzapine Neuropsychiatric Disease and Treatment 2007:3(1) 178
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in the present study.  Another possibility is the influence 
of racial differences. Asian people have reduced insulin 
secretion compared with Caucasians (Sasahara et al 
2004), making it theoretically more difficult to detect 
metabolic abnormalities from fasting blood samples. This 
could explain why insulin resistance was not detected in 
our group of Japanese patients. The glucose tolerance 
test is clearly useful for earlier detection of lipid meta-
bolic abnormalities. This is especially true for Japanese 
patients who have reduced insulin secretion compared 
with Caucasians and their metabolic abnormalities are 
not easily detected by conventional markers.
Higher levels of RLP-cholesterol have recently been sug-
gested to be a risk factor for arteriosclerosis (Takeichi et al 
1999). In a 3-year follow-up study of patients with coronary ar-
tery disease, patients with higher RLP-cholesterol (>5.1 mg/dL) 
had a signiﬁ  cantly greater risk of developing coronary events 
than lower RLP-cholesterol patients (<3.3 mg/dL) (Kugiyama 
et al 1999). The present study suggests that patients treated 
with olanzapine should be routinely tested using the glucose 
tolerance cookie test to determine RLP-cholesterol level as a 
risk marker for the development of coronary events. 
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resulted in elevated serum insulin levels compared to baseline 
values in a 5-month study (Melkersson et al 2000).
These studies suggest that certain antipsychotics can 
induce insulin resistance. It is not clear, however, from these 
studies whether the effect results from metabolic syndromes, 
such as weight gain and obesity, or a direct effect.   
Evidence for a direct effect is accumulating. A recent 
study of non-obese, non-diabetic schizophrenics showed 
elevated fasting insulin levels with clozapine and olanzapine 
(Henderson et al 2005). In this study, insulin resistance was 
signiﬁ  cantly reduced in patients on clozapine or olanzapine 
compared with those on risperidone. In addition, in vitro stud-
ies have shown a direct effect of clozapine and olanzapine but 
not conventional antipsychotics on the stimulation of insulin 
secretion from pancreatic β-cells (Melkersson 2004).
In the present study, non-obese and non-diabetic patients 
were selected, so that any lipid metabolic abnormalities 
that were seen were not due to any metabolic syndrome. 
Although no insulin resistance was found in the olanzap-
ine treatment group, high levels of triglyceride and RLP-
cholesterol were induced by the glucose tolerance cookie 
test. This suggests that olanzapine has a direct action on 
lipid metabolism even after relatively short treatment dura-
tion (3–24 weeks).
In contrast to the study by Henderson et al (2005), the 
present study in non-obese, non-diabetic subjects found no 
difference between patients treated with olanazpine and 
risperidone in fasting insulin levels which were all within 
the normal range. A possible reason for this difference be-
tween the studies may be the duration of drug treatment. In 
the Henderson study, the mean duration of treatment with 
olanzapine was 29.5 months, whereas it was only 12.3 weeks 
Table 1  Carbohydrate and lipid metabolism markers
 Risperidone-  Olanzapine-treated
 treated  patients  patients
  n = 9  n = 9
Glucose (mg/dL)– fasting  88.1 ± 8.1  92.6 ± 10.5
  • after glucose tolerance cookie  99.6 ± 9.7  109.0 ± 15.0*
Insulin (μU/L)–fasting  5.4 ± 2.6  5.5 ± 3.3
  • after glucose tolerance cookie  7.8 ± 1.8**  9.1± 2.3*
Triglycerides (mg/dL)–fasting  120.9 ± 27.4  130.4 ± 33.6
  • after glucose tolerance cookie  132.6 ± 24.2  171.2 ± 41.7*
Total cholesterol (mg/dL)–fasting  165.2 ± 42.4  171.2 ± 34.5
HDL cholesterol (mg/dL)–fasting   48.8 ±12.7  48.2 ±13.1
RLP-cholesterol (mg/dL)  4.3 ± 1.6  7.5 ± 1.0 † 
Insulin resistance (HOMA-IR)– fasting   1.19 ± 0.6  1.23 ± 0.7
All values are mean ± SD.
*p < 0.05  ** p < 0.01 compared with fasting values.
†p < 0.05 compared with risperidone. Neuropsychiatric Disease and Treatment 2007:3(1) 179
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